診療科・部門

トップページ診療科・部門乳腺科部研究実績

研究実績

令和4年3月改訂

英文論文

2021年

  1. Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Yuri Ozaki Y, Sugino K, Kataoka A, Kotani H, Yoshimura A, Hattori M, Sawaki M, Iwata H. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2‑low and HER2‑negative breast cancer by HR status. Breast Cancer. https://doi.org/10.1007/s12282-021-01303-3
  2. Mori M, Yoshimura A, Sawaki M, Hattori M, Kotani H, Adachi A, Iwase M, Kataoka A, Sugino K, Horisawa N, Ozaki Y, Iwata H, Onishi S, Gondo N and Terada M. Differences in baseline risk estimated by physicians and patients with early breast cancer. Jpn J Clin Oncol 51: 1703-1707, 2021
  3. Ozaki Y, Yoshimura A, Sawaki M, Hattori M, Kotani H, Adachi Y, Kataoka A, Sugino K, Horisawa N, Endo Y, Nozawa K, Sakamoto S, Takatsuka D, Okumura S, Maruyama Y, Iwata H. The significance of biopsy scar excision at the time of skin- or nipple-sparing mastectomy with immediate breast reconstruction. Jpn J Clin Oncol 51: 1212-1218, 2021
  4. Adachi Y, Oze I, Sawaki M, Hattori M, Yoshimura A, Kotani H, Kataoka A, Sugino K, Horisawa N, Ozaki Y, Endo Y, Nozawa K, Takatsuka D, Iwata H. Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer. Breast Cancer 28: 1087-1095, 2021
  5. Kotani H, Terada M, Mori M, Horisawa N, Sugino K, Kataoka A, Adachi Y, Gondou N, Yoshimura A, Hattori M, Sawaki M, Takahata C, Kobara M and Iwata H.  Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: Results from a double-blind phase 2 trial. BMC Cancer 21:548, 2021
  6. Maeda A, Irie K, Hashimoto N, Fukushima S, Ando H, Okada A, Ebi H, Kajita M, Iwata H, Sawaki M. Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. Invest New Drugs 39: 272-277, 2021.
  7. Sawaki M, Yamada A, Kumamaru H, Miyata H, Nakayama K, Shimizu C, Miyashita M, Honma N, Taira N and Saji S. Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan. Breast Cancer 28: 1-8, 2021
  8. Nozawa K, Yoshimura A, Iwata H. Adjuvant Olaparib in BRCA-Mutated Breast Cancer. N Engl J Med 385: 1439, 2021
  9. Iwata H, Umeyama Y, Liu Y, Zhang Z, Schnell P, Mori Y, Fletcher O, Marshall JC, Johnson JG, Wood LS, Toi M, Finn RS, Turner NC, Bartlett CH, Cristofanilli M. Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3. Oncologist 26: e1143-e1155, 2021

2020年

  1. Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, MizunoT, Yamamoto Y, Iwata H, Kawahara T, Ohashi Y and Mukai H. Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-positive Early Breast Cancer in Older Patients. J Clin Oncol 38: 3743-3752, 2020
  2. Sugino K, Horisawa N, Endo Y, Nozawa K, Sakamoto S and Iwata H. Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report. World J Clin Oncol 11: 504-509, 2020
  3. Gondo N, Sawaki M, Hattori M, Yoshimura A, Kotani H, Adachi Y, Kataoka A, Sugino K, Horisawa N, Ozaki Y, Endo Y, Iwata H. Utility of regional nodal irradiation in Japanese patients with breast cancer with 1-3 positive nodes after breast-conserving surgery and axillary lymph-node dissection. Mol Clin Oncol 13: 48-53, 2020
  4. Adachi Y, Okumura S, Sawaki M, Hattori M, Yoshimura A, Gondo N, Kotani H, Iwase M, Kataoka A, Sugino K, Horisawa N, Ozaki Y, Endo Y, Sakamoto S, Iwata H. Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients undergoing immediate breast reconstruction. Breast Cancer 27:716-723, 2020
  5. Gondo N, Sawaki M, Hattori M, Yoshimura A, Kotani H, Adachi Y, Kataoka A, Sugino K, Mori M, Horisawa N, Terada M, Ozaki Y, Iwata H. Impact of BMI for clinical outcomes in Japanese breast cancer patients. Jpn J Clin Oncol 50: 230-240, 2020
  6. Hattori M, Nakanishi H, Yoshimura M, Iwase M, Yoshimura A, Adachi Y, Gondo N, Kotani H, Sawaki M, Fujita N, Yatabe Y, Iwata H. Circulating tumor cells detection in tumor draining vein of breast cancer patients. Sci Rep. 2019 Dec 3;9(1):18195. doi: 10.1038/s41598-019-54839-y.
  7. Terada M, Yoshimura A, Sawaki M, Hattori M, Naomi G, Kotani H, Adachi Y, Iwase M, Kataoka A, Sugino K, Mori M, Horisawa N, Ozaki Y, Iwata H. Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors. Breast Cancer Res Treat 179: 91-100, 2020
  8. Iwata H, Saji S, Ikeda M, Inokuchi M, Uematsu T, Toyama T, Horii R, Yamauchi C. The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient. Breast Cancer 27: 1-3, 2020

2019年

  1. Sawaki M, Miyamoto T, Fujisawa T, Itoh Y, Ebara T, Tachibana H, Kodaira T, Kikumori T, Yanagita Y, Iwata H. Multicenter phase II study of intraoperative radiotherapy of early breast cancer: Ipsilateral tumor recurrence. Ann Surg Oncol 26: 2428–2434, 2019
  2. Sawaki M, Kodaira T, Iwata H. ASO Author Reflections: The strengths and weaknesses of intraoperative radiotherapy for early breast cancer and Ipsilateral tumor recurrence. Ann Surg Oncol 26: S660–S661, 2019
  3. Sawaki M, Shien T, Iwata H. TNM Classification of Malignant Tumors (Breast Cancer Study Group: BCSG). Jpn J Clin Oncol 49: 228-231, 2019
  4. Ozaki Y, Yoshimura A, Sawaki M, Hattori M, Gondo N, Kotani H, Adachi Y, Kataoka A, Iwase M, Hattori M, Sawaki M, Yoshimura A, Kotani H, Gondo N, Adachi Y, Kataoka A, Onishi S, Sugino K, Horisawa N, Mori M, Terada M, Iwata H. Presence of small residual malignant lesions in pathologic complete response after neoadjuvant chemotherapy in patients with breast cancer. Breast J 25:1303-1305, 2019
  5. Hattori M, Hagiwara S, Kotani H, Tatematsu M, Mizuno Y, Tachi M, Hijioka S, Shimizu J, Ando M, Sawaki M, Yoshimura A, Gondo N, Adachi Y, Yoshimura K, Iwata H. A single arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types. Int J Clin Oncol 24: 1320-1327, 2019
  6. Terada M, Gondo N, Sawaki M, Hattori M, Yoshimura A, Kotani H, Adachi Y, Iwase M, Kataoka A, Sugino K, Mori M, Horisawa N, Ozaki Y, Iwata H. A case of giant cell tumor of the breast clinically suspected as malignant breast tumor. Surg Case Rep 2019; 5: 77
  7. Mori M, Kotani H, Sawaki M, Hattori M, Yoshimura A, Gondo N, Adachi Y, Kataoka A, Sugino K, Horisawa N, Terada M, Ozaki Y, Iwata H. Amyloid tumor of the breast. Surg Case Rep 5: 31, 2019
  8. Onishi S, Sawaki M, Ishiguro J, Kataoka A, Iwase M, Sugino K, Adachi Y, Gondo N, Kotani H, Yoshimura A, Hattori M, Matsuo K, Yatabe Y, and Iwata H. Overall survival of breast cancer patients without adjuvant therapy. Surg Today 49: 610-620, 2019
  9. Kataoka A, Sawaki M, Okumura S, Onishi S, Iwase M, Sugino K, Ishiguro J, Gondo N, Kotani H, Yoshimura A, Hattori M, Sasaki E, Yatabe Y, Yoshimura K, Ohmi K and Iwata H. Prediction of pathological margin status using preoperative contrast-enhanced MRI in patients with early breast cancer who underwent skin-sparing mastectomy. Breast J 25: 202–206, 2019
  10. Iwata H, Inoue K, Kaneko K, Ito Y, Tsugawa K, Hasegawa A, Nakagawa S, Kuratomi H, Tamura K. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Jpn J Clin Oncol 49: 1083-1091, 2019
  11. Iwata H, Masuda N, Kim SB, Inoue K, Rai Y, Fujita T, Chiu J, Ohtani S, Takahashi M, Miyaki T, Lu YS, Xu B, Yap YS, Bustam A, Yao B, Zhang B, Bryce R, Chan A. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. Future Oncol 15: 2489-2501, 2019

Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat 173: 123-133, 2019【2013年度】